Literature DB >> 28212845

Safety assessment of medium- and long-chain triacylglycerols containing 30% (w/w) medium-chain fatty acids in mice and rats.

Shengmin Zhou1, Yueqiang Wang2, Yuanrong Jiang2, Liangli Lucy Yu3.   

Abstract

A novel medium- and long-chain triacylglycerols (MLCT), with 30% (w/w) medium-chain fatty acids (MCFA) was evaluated for its safety as a dietary fat in mice and rats. The subacute oral toxicity study showed that the maximum tolerated dose exceeded 54.33 g/kg body weight (kg bw)/day. In the 90-day feeding study, no dose-related adverse effects were observed in rats administered diets formulated with different levels of MLCT (2.0, 4.0, and 8.0 g/kg bw/day) as compared to the rapeseed oil control diet. Further safety assessment in pregnant rats did not reveal any significant difference relative to the control at a treatment level up to 8.0 g MLCT/kg bw/day. The results from this study indicated the safe use of MLCT with high contents of MCFA in food products for improving human health.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  90-Day feeding study; Embryotoxicity study in pregnant rats; Medium- and long-chain triacylglycerols; Safety assessment; Subacute oral toxicity study

Mesh:

Substances:

Year:  2017        PMID: 28212845     DOI: 10.1016/j.yrtph.2017.02.007

Source DB:  PubMed          Journal:  Regul Toxicol Pharmacol        ISSN: 0273-2300            Impact factor:   3.271


  2 in total

1.  Effects of medium- and long-chain fatty acids on acetaminophen- or rifampicin-induced hepatocellular injury.

Authors:  Jun Yang; Ting Peng; Jiyong Huang; Guohua Zhang; Jiaheng Xia; Maomao Ma; Danwen Deng; Deming Gong; Zheling Zeng
Journal:  Food Sci Nutr       Date:  2020-05-19       Impact factor: 2.863

2.  Enhanced gastric therapeutic effects of Brucea javanica oil and its gastroretentive drug delivery system compared to commercial products in pharmacokinetics study.

Authors:  Yue Zhang; Liying Zhang; Qi Zhang; Xitong Zhang; Tong Zhang; Bing Wang
Journal:  Drug Des Devel Ther       Date:  2018-03-13       Impact factor: 4.162

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.